top of page
Pharma & biotech collaborations
Covers research and drug development collaborations between human-based in vitro developers and pharma/biotech


Prellis Biologics joins forces with Eli Lilly to transform how target-specific human antibodies are generated
24 September 2025 Berkeley-based Prellis Biologics, Inc. , developer of human in vitro antibody generation platform, announces collaboration with Eli Lilly to accelerate the discovery of human antibodies for multiple disease targets. Prellis’ EXIS™ lymph node platform for target‑specific human antibody generation is a shining example of ingenuity by which several technologies were combined to capture human-relevant physiology. The traditional method of antibody generat
Heartbeat.bio partners with Boehringer Ingelheim to develop a gene therapy for cardiomyopathy
23 September 2025 Vienna-based Heartbeat.bio , developer of breakthrough therapies for cardiac disorders through its proprietary human-based in vitro cardioid drug discovery platform, announces it has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. Genetic cardiac pathologies such as hypertrophic, dilated, arrhythmogenic right ventricular and restrictive cardiomyopathy, are typically c
Mimetas partners with Attivare Therapeutics to accelerate innovation in cancer research
16 December 2025 Put in place to accelerate the development of innovative cancer therapies through collaboration initiatives, the Netherlands-based Oncode Accelerator program announces launching of its Demonstrator Project. Through this project, researchers and drug developers will be able to share expertise, experimental platforms, and infrastructure to advance novel therapeutic approaches. Recent advances in cancer therapies and in particular immunotherapy have produce
bottom of page
